cytochrome P450 family 2 subfamily A member 7Genealiases: CPA7 · CPAD · CYP2A · CYPIIA7 · P450-IIA4
Q-omics provides the consensus-scored CYP2A7 profile across patient tissues and cancer cell-line models. CYP2A7 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CYP2A7 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, CYP2A7 RNA expression shows 15,451 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, LIHC, and THYM as cancer lineages where CYP2A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2A7 survival associations across molecular data types. CYP2A7 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2A7 RNA expression–survival associations across cancer types. High CYP2A7 expression shows unfavorable associations in DLBC, THCA and KIRC, but favorable associations in LIHC, HNSC and BRCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for CYP2A7 RNA expression.
This table summarizes CYP2A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2A7 shows lower tumor expression in LIHC, CHOL, LUSC, UCEC and LUAD. The LIHC box plot shows higher CYP2A7 RNA expression in normal versus tumor tissue (log2 FC = −3.593, t-test p < 0.001).
This table shows molecular features associated with CYP2A7 in patient tissues and cancer cell lines. In patient samples, CYP2A7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
